Value of Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer: A European Perspective.

J Clin Oncol

Christina Fotopoulou, Imperial College London, London, United Kingdom; Jalid Sehouli, Charité Medical University of Berlin, Berlin, Germany; Giovanni Aletti, European Institute of Oncology, Milan, Italy; Philipp Harter, Kliniken Essen Mitte, Essen, Germany; Sven Mahner, Ludwig-Maximilians-University, Munich, Germany; Denis Querleu, Institut Bergonié, Bordeaux, France; Luis Chiva, Clínica Universidad de Navarra, Navarra, Spain; Hani Gabra, Imperial College London, London, United Kingdom; Nicoletta Colombo, European Institute of Oncology, Milan, Italy; and Andreas du Bois, Kliniken Essen Mitte, Essen, Germany.

Published: February 2017

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.0723DOI Listing

Publication Analysis

Top Keywords

neoadjuvant chemotherapy
4
chemotherapy newly
4
newly diagnosed
4
diagnosed advanced
4
advanced ovarian
4
ovarian cancer
4
cancer european
4
european perspective
4
neoadjuvant
1
newly
1

Similar Publications

Background: Neoadjuvant therapy is recommended for treating resectable pancreatic ductal adenocarcinoma (PDAC); however, its appropriate use in patients with resectable PDAC remains debatable.

Objective: This study aimed to identify independent poor prognostic factors and evaluate the clinical significance of neoadjuvant therapy in patients with resectable PDAC.

Methods: We retrospectively reviewed consecutive patients diagnosed with resectable PDAC at our institute between January 2003 and December 2022.

View Article and Find Full Text PDF

Since the adoption of neoadjuvant chemoradiation and total mesorectal excision as the standard in rectal cancer care, there has been marked improvement in the local recurrence rates. In this context, restaging magnetic resonance imaging (MRI) plays a key role in the assessment of tumor response, occasionally enabling organ-sparing approaches. However, the role of restaging MRI in evaluating lateral lymph nodes remains limited.

View Article and Find Full Text PDF

Who is a candidate at the initial presentation? Prediction of positive lateral lymph node and survival after dissection.

Tech Coloproctol

January 2025

Department of Colorectal Surgery, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, 222 Banpodearo, Seochogu, Seoul, 06591, Korea.

Metastatic lateral pelvic lymph node (LPN) in rectal cancer has a significant clinical impact on the prognosis and treatment strategies. But there are still debates regarding prediction of lateral pelvic lymph node metastasis and its oncological impact. This review explores the evidence for predicting lateral pelvic lymph node metastasis and survival in locally advanced rectal cancer.

View Article and Find Full Text PDF

Background: Incomplete mesorectal excision during rectal cancer surgery often leads to positive circumferential margins, with uncertain prognostic impacts. This study examines whether negative margins can mitigate the poorer prognosis typically associated with incomplete total mesorectal excision (TME) in rectal cancer surgery, thus potentially challenging the prevailing emphasis on complete mesorectal excision.

Patients And Methods: A retrospective analysis was conducted on patients who underwent proctectomy for rectal adenocarcinoma with incomplete TME at a single center from 2010 to 2022.

View Article and Find Full Text PDF

The oncologic benefits of lateral lymph node dissection after neoadjuvant therapy - local control or survival?

Tech Coloproctol

January 2025

Colorectal Unit, Department of Surgery, Royal Adelaide Hospital, Port Road, SA, 5000, Australia.

Lateral pelvic lymph node dissection (LPLND) for rectal adenocarcinoma is an established treatment modality for selected patients with abnormal lateral pelvic lymph nodes on magnetic resonance imaging (MRI) imaging. The goal of this treatment is to achieve a true R0 resection, including lymphadenectomy, with the aim of improving patient oncological outcome, potentially at the expense of surgical and functional complications. However, there remain several areas of controversy resulting from a distinct lack of clarity regarding effective patient selection, lymph node size criteria, the role and extent of routine neoadjuvant treatment versus surgery alone in selected cases, the impact on patient survival metrics and whether the existing data are even valid in the era of total neoadjuvant therapy (TNT).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!